As a growth ETF, RPG accentuates biotech, medical device and specialty pharmaceuticals stocks over blue chip pharma names. Of RPG’s 17 healthcare holdings, six are biotech stocks and three are medical device manufacturers. [Why This Healthcare ETF is Surging]
“In addition to reviewing holdings, we focus on ETF level attributes. RPG is above its 200-day moving average and has bullish technical tendencies according to S&P Capital IQ. In addition, the 0.35% expense ratio is relatively modest compared to the broader equity ETF universe. On average, 175,000 shares trade on a daily basis and with a $0.03 bid/ask spread. Meanwhile, the ETF trades at a 4 basis point premium to its net asset value,” said S&P Capital IQ.
Investors have allocated $202.6 million to RPG this year after pouring $758.3 million into the ETF last year. RPG charges 0.35% per year.
Guggenheim S&P 500 Pure Growth ETF
